Importantly, a study from Lin et al. have demonstrated in a mice model of UC-related colorectal cancer (AOM/DSS mice model) that celastrol increases survival rate associated with a reduction in colonic neoplasms, prevents the upregulation of oncogenic markers namely, β-catenin, proliferating cell nuclear antigen (PCNA), and dysfunctional p53, inhibits proinflammatory mediators and NF-kB activation and suppresses epithelial mesenchymal transition (EMT), through E-cadherin upregulation and N-cadherin, vimentin, and Snail downregulation (69). Here, PCNA is linked to colonic neoplasm.